A post-marketing surveillance study of Euhypnos (temazepam), a new short-acting benzodiazepine hypnotic. A total of 12,350 patients requiring a sleep inducer were treated for up to 3 months with doses of 10–30 mg at night. After 2 weeks 80% of First Reports (FRs) rated Euhypnos effective and at 3 months this had risen to 92% of 3062 Second Reports (SRs). Hangover was reported in 7% of FRs and 2% of SRs but in general the drug was well tolerated with adverse reactions consisting mainly of morning nausea, headache, drowsiness and vivid dreaming. Eighty-seven per cent of FRs and 93% of SRs were ‘Clean’ reporting no hangover, adverse reaction or event of any kind.
Get full access to this article
View all access options for this article.
References
1.
DolleryC TRawlinsM D (1977) Monitoring adverse reactions to drugs. British Medical Journal1, 96.
2.
FowlerL K (1979) Euhypnos® Forte (temazepam) for resistant insomnia: post-marketing surveillance, an interim report. Journal of International Medical Research7, 379.
3.
HindmarchIParrottA CHIckeyB JClydeC A (1980) An investigation into the effects of repeated doses of temazepam (40 mg and 60 mg) on aspects of sleep, early morning behaviour and psychomotor performance in normal subjects. Drugs Under Experimental and Clinical Research (In press).
4.
LawsonD GHenryD A (1977) Monitoring adverse reactions to new drugs: ‘restricted release’ or ‘monitored release’?British Medical Journal1, 691.
5.
Medico-Pharmaceutical Forum (1977) Post-marketing surveillance of adverse reactions to new medicines, London.
6.
WilsonA B (1977) Post-marketing surveillance of adverse reactions to new medicines. British Medical Journal1, 1001.
